Geode Capital Management
GENB icon

Geode Capital Management’s Generate Biomedicines GENB Stock Holding History

Geode Capital Management’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4M Buy
735,003
+616,760
+522% +$8.4M ﹤0.01% 2426
2026
Q1 		$1.48M Buy
+118,243
New +$1.44M ﹤0.01% 3232

Other funds holding GENB

Flagship Pioneering
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Braidwell
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Arch Venture Management
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Harbourvest Partners
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Geode Capital Management's GENB Position: Q2 2026 in Review

Geode Capital Management increased its Generate Biomedicines (GENB) stake by 522% in Q2 2026, buying an estimated $8.4M and bringing the position to 735,003 shares worth $12.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2426.

Geode Capital Management first reported a position in GENB in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Geode Capital Management held 735,003 shares of Generate Biomedicines worth $12.4M as of Q2 2026.
  • Geode Capital Management bought 616,760 Generate Biomedicines shares in Q2 2026, an estimated $8.4M.
  • Generate Biomedicines made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2426 holding.
  • Geode Capital Management first reported a position in Generate Biomedicines in Q1 2026 and has held it in 2 quarters since.
  • 86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.